{
  "id": "chatcmpl-A3U7UzqOWdqxomx577P5rT9gRxt5I",
  "choices": [
    {
      "finish_reason": "stop",
      "index": 0,
      "logprobs": null,
      "message": {
        "content": "41fx | Effect of Tilarginine Acetate in Patients With Acute Myocardial Infarction and Cardiogenic Shock, twenty zero seven fifty-three\n7um8 | A Comparison of Epinephrine and Norepinephrine in Critically Ill Patients, twenty zero eight forty-two\nuow2 | Study\niat7 | with worse metabolic acidosis and increased lactate levels; those treated with epinephrine experienced significantly greater increases in heart rate and a concomitant increase in the cardiac double product, an indirect surrogate of myocardial oxygen consumption, compared with norepinephrine treated patients; and the study was terminated prematurely due to increased rates of refractory CS odds ratio eight point two four developing in the epinephrine-treated arm. Additionally, a meta-analysis that included two thousand five hundred eighty-three patients with nonsurgical CS assessed the impact of epinephrine treatment on short-term mortality outcomes. This study found that epinephrine treated patients had significantly greater adjusted risk of mortality adjusted odds ratio four point seven. Epinephrine's apparent lack of benefit relating to hemodynamic parameters, increased myocardial oxygen consumption, and the potential increased risk of developing refractory CS and death, when compared with norepinephrine, raise concerns about its use as a first-line treatment in CS. However, further data are required to establish norepinephrine's superiority over epinephrine as the first-line therapy in CS with hypotension.\nywwr | Treatment Cardiogenic Shock With Preserved Blood Pressure and Low Cardiac Output State\n0i6j | To date there are no randomized studies comparing the safety and efficacy of inotropes with inodilators in CS. There are three commonly administered inodilators\n87cq | Vasoactive Medications in Cardiogenic Shock\n0qs3 | in clinical practice, each with a unique mechanism of action; beta one- and beta two-AR agonist, dobutamine; PDE three inhibitors such as milrinone; and the calcium sensitizer, levosimendan (not routinely available in the United States). Although these agents increase myocardial contractility and lusitropy like traditional inotropes, they also have the effect of reducing cardiac afterload through vasodilation. The use of milrinone and dobutamine has recently been compared through the CAPITAL DOREMI (Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock) study, a single-center, double-blinded randomized controlled trial. This study included one hundred ninety-two patients (ninety-six participants in each treatment arm) admitted to ICU with CS and randomized to receive either milrinone or dobutamine. There was no difference in the primary composite outcome of in-hospital mortality, resuscitated cardiac arrest, cardiac transplantation or mechanical circulatory support, nonfatal myocardial infarction, stroke, or renal replacement therapy relative risk zero point nine. In a prespecified subgroup analysis, which included sixty-five patients with AMI-CS, there was also no significant difference in the primary composite outcome between agents hazard ratio one point three five. However, the findings from this study should be interpreted with a degree of caution due to its small sample size potentially rendering the trial underpowered to detect the smaller than anticipated treatment effects in both the primary composite and secondary outcomes. Furthermore, its generalizability to other clinical settings may be limited as it was a single-center study conducted in a quaternary level ICU. Nevertheless, considering these findings,\nz8f7 | patients who are normotensive and in a low cardiac output state, it is reasonable to consider the administration of either dobutamine or milrinone as a first-line therapy, with the exception of severe renal impairment where dobutamine should be used in preference to milrinone.\n7w7j | Vasoactive Medications in Refractory Hypotension\n51vd | The treatment of refractory hypotension in CS represents a significant challenge. In the setting of severe metabolic acidosis, which occurs due to tissue hypoxia and subsequent activation of anaerobic metabolic pathways, both in vivo and ex vivo experimental data has demonstrated reduced vascular and cardiac responsiveness to catecholamines. The relatively preserved vasopressor effects in the setting of acidosis of vasopressin and methylene blue render these drugs a reasonable choice to trial as salvage therapy in cases of catecholamine-refractory vasoplegia.\nbaj1 | A STEPWISE APPROACH TO VASOACTIVE THERAPY IN CARDIOGENIC SHOCK\nn1wo | Presented in Figure four is a proposed stepwise approach for the use of vasoactive agents in CS. In the initial phase of therapy, we suggest that patients should be stratified into two phenotypes, those with hypotension (systolic blood pressure less than ninety millimeters of mercury, MAP less than or equal to sixty-five millimeters of mercury, or greater than thirty-millimeter mercury reduction in MAP from baseline with evidence of hypoperfusion) or low cardiac output (determined clinically, biochemically, or through an invasive hemodynamic assessment) and preserved blood pressure. The algorithm advocates for the initial correction of hypotension, followed by the treatment of the low cardiac output state with the use of inodilator therapy. The timing and role for the use of MCS in this clinical situation remains less certain and is outside the scope of this review. However, persistent severe CS should prompt clinician consideration for MCS therapy at any stage of the proposed treatment pathway. This strategy leverages the emerging data supporting the use of norepinephrine as a first-line therapy, while emphasizing the need for ongoing and repeated assessment throughout the treatment journey to tailor therapy based on the current prevailing hemodynamic status.\n5bq3 | Assessing Response to Therapy and Requirement for Titration of Hemodynamic Supports Invasive Monitoring\nezla | Continuous blood pressure monitoring is essential to assess for progression of the underlying disease\nrsbu | Vasoactive Medications in Cardiogenic Shock\nmagd | process and the therapeutic response to vasoactive therapy. The MAP, defined as the average blood pressure during a cardiac cycle, can be equated to the end-organ \"perfusion pressure.\" Accordingly, MAP is often used as treatment target for patients with CS and has been incorporated into the proposed treatment algorithm. The literature guiding specific MAP targets in a population with CS is limited and largely supported by observational data. Nonetheless, current guidelines suggest a target MAP of greater than or equal to sixty-five millimeters of mercury.",
        "role": "assistant",
        "function_call": null,
        "tool_calls": null,
        "refusal": null
      }
    }
  ],
  "created": 1725394128,
  "model": "gpt-4o-2024-05-13",
  "object": "chat.completion",
  "system_fingerprint": "fp_fde2829a40",
  "usage": {
    "completion_tokens": 1311,
    "prompt_tokens": 3176,
    "total_tokens": 4487
  }
}